Related Experiment Video

Updated: Mar 8, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

[Research Progress of Targeted Therapy for Anaplastic Lymphoma Kinase and Other Rare Driver Genes in Advanced

Quan Zhang1, Shucai Zhang1

  • 1Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor 
Research Institute, Beijing 101149, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|January 21, 2017
PubMed

Insights

Targeted therapy is crucial for advanced non-small cell lung cancer (NSCLC) with driver mutations. This review covers new treatments and resistance mechanisms for anaplastic lymphoma kinase (ALK) and rare targets in NSCLC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Targeted therapy is a cornerstone treatment for advanced non-small cell lung cancer (NSCLC) harboring specific driver gene alterations.
  • Continuous advancements in identifying novel targets and developing new drugs are rapidly evolving this field.
  • Understanding the molecular basis of both intrinsic and acquired resistance to targeted agents is critical for improving patient outcomes.

Purpose of the Study:

  • To provide a comprehensive overview of recent developments in targeted therapy for NSCLC.
  • To focus on treatments targeting anaplastic lymphoma kinase (ALK) and other less common driver mutations.
  • To summarize current knowledge on resistance mechanisms to targeted therapies in NSCLC.

Main Methods:

  • Literature review of recent research on targeted therapy in NSCLC.
  • Analysis of studies focusing on anaplastic lymphoma kinase (ALK) and other rare driver genes.
  • Synthesis of information regarding molecular mechanisms of resistance.

Main Results:

  • Significant progress has been made in discovering new targets and developing novel drugs for NSCLC.
  • Anaplastic lymphoma kinase (ALK) rearrangements remain a key focus for targeted treatment strategies.
  • Emerging research is shedding light on the complex mechanisms of resistance to these therapies.

Conclusions:

  • Targeted therapy continues to be a rapidly advancing and essential treatment modality for advanced NSCLC.
  • Further research into novel targets, drug development, and overcoming resistance is warranted.
  • Personalized treatment approaches based on specific genetic profiles are crucial for optimizing NSCLC management.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

493
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60